Doximity, Inc. (NASDAQ:DOCS) Shares Sold by American Century Companies Inc.

American Century Companies Inc. cut its stake in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 47.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 111,927 shares of the company's stock after selling 100,402 shares during the period. American Century Companies Inc. owned about 0.06% of Doximity worth $5,976,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Shaker Investments LLC OH acquired a new position in shares of Doximity during the 4th quarter worth about $559,000. Principal Financial Group Inc. increased its holdings in shares of Doximity by 1.5% in the fourth quarter. Principal Financial Group Inc. now owns 293,974 shares of the company's stock valued at $15,695,000 after purchasing an additional 4,282 shares during the period. Newbridge Financial Services Group Inc. purchased a new position in Doximity during the 4th quarter worth $362,000. Stratos Wealth Partners LTD. acquired a new stake in Doximity in the fourth quarter valued at about $203,000. Finally, Barclays PLC lifted its holdings in shares of Doximity by 60.5% in the 3rd quarter. Barclays PLC now owns 53,401 shares of the company's stock valued at $2,327,000 after buying an additional 20,125 shares during the period. 87.19% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently commented on DOCS shares. Mizuho boosted their price objective on shares of Doximity from $55.00 to $65.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Canaccord Genuity Group upped their target price on shares of Doximity from $60.00 to $71.00 and gave the company a "hold" rating in a report on Friday, February 7th. Piper Sandler upgraded Doximity from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $31.00 to $78.00 in a report on Friday, February 7th. Raymond James reaffirmed an "outperform" rating and set a $83.00 price target (up from $65.00) on shares of Doximity in a research report on Friday, February 7th. Finally, Bank of America raised their target price on Doximity from $54.00 to $57.00 and gave the company a "neutral" rating in a report on Monday, January 6th. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Doximity has a consensus rating of "Moderate Buy" and an average price target of $64.22.

Doximity Trading Up 9.6 %

DOCS traded up $4.88 during trading on Wednesday, reaching $55.59. 3,339,694 shares of the company were exchanged, compared to its average volume of 1,966,247. The firm has a 50 day moving average of $65.02 and a 200 day moving average of $55.34. The stock has a market cap of $10.38 billion, a P/E ratio of 55.59, a PEG ratio of 4.10 and a beta of 1.41. Doximity, Inc. has a 52 week low of $22.96 and a 52 week high of $85.21.

Insider Activity at Doximity

In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of Doximity stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the sale, the director now owns 6,360 shares of the company's stock, valued at $366,463.20. The trade was a 75.87 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 37.40% of the stock is currently owned by insiders.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.